The Threshold of Skin Flare in Persons with and Without Malignant Neoplastic Disease12  by Benjamin, F.B. & Ivy, A.C.
THE THRESHOLD OF SKIN FLARE IN PERSONS WITH AND
WITHOUT MALIGNANT NEOPLASTIC DISEASE*t
F. B. BENJAMIN, D.M.D., M.S., AND A. C. IVY, PH.D., M.D.
INTRODUCTION
The threshold of pain is identified as the lowest intensity at which a noxious
excitant when applied for an arbitrary time, such as one second, will produce a
painful or a pricking sensation. The threshold of the skin flare reaction is identified
as the lowest intensity at which a noxious excitant when applied for an arbi-
trary time, such as one minute, will cause a flare reaction or "blush" about the
point of application of the excitant.
Since it is important to use an excitant which can be controlled and measured
accurately, heat was used in this study. We have arbitrarily required the red-
dened area to measure at least 15 mm. in its largest diameter, when the area of
contact of the excitant is not greater than 3 mm. in diameter. This requirement
is established to avoid the possibility of confusing the local "red spot" or "red
reaction," which occurs at the point of application of the noxious excitant, with
the flare reaction. The flare reaction is a larger, more diffuse reddening and is
due to a local nervous axon reflex resulting in a dilation of the blood vessels of
the skin.
Considerable evidence indicates that the flare reaction is due to the release
of histamine or a histamine-like substance (H-substance) at the point of con-
tact of the noxious excitant (1). The H-substance presumably stimulates the
sensory branch of an axon reflex which results in the vasodilation for one or more
centimeters about the point of contact.
As a result of our general interest in the physiology of pain (2, 3, 4), we be-
came interested in ascertaining whether a ratio exists between the threshold of
pain and the threshold of flare. During the course of this study, it was found that
patients with malignant neoplastic disease had an abnormally high threshold
of flare as compared to clinically normal persons and to patients with arthritis
who, like some cancer patients, suffered from rather severe pain. Our study on
skin flare was then extended to determine to what extent a high threshold of
skin flare is specific to malignant neoplastic disease.
METHODS
Apparatus No. I: The initial apparatus used for applying a graduated amount of heat to
the skin was quite simple (Figure 1). The applicator was made of 26 gauge insulated ni-
chrome wire. A single strand 4'6" long was folded on itself to form a cord 27 inches long. The
insulation was removed from the point of bending and this point of the wire was flattened
to make an applicator tip with a "U" shaped contact with the skin of approximately 1:1:1
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millimeter. The two-ends of the applicator were coooected io series with a 1.5 volt dry cell,
a rheostat, and a milliammoter*.
Method of Performing the Test: To determine the threshotd of pain, the current was turned
on at a milliammeter reading of 400. The tip was allowed to heat in the air (room temper-
ature) for 30 seconds, then brought into contact with the skin of the inner upper aspect of
the forearm for 1 second (count 1001) and removed. This was repeated 5 times. The threshold
of pain was taken as that milliammeter reading at which the subject reported a pricking
pain on at least 2 out of 5 contacts. The reading usually ranged from 425 to 800 ma. in dif-
ferent subjects.
To determine the threshold of flare, the milliammeter reading was set at 600, and the tip
of the applicator was allowed to heat in the air (room temperature) for 30 seconds. The tip
was then placed into contact with the skin using only the pressure of its own weight, for one
minute. If a flare did not occur at 600 ma., the current was increased to 625 ma., and then in
increments of 25 ma. until a flare reaction was obtained. A new area of skin 2 or 3 cm. distant
was used for each trial.
The threshold of flare was taken as that milliammeter reading at which a flare appeared
about the contact of the tip. The flare must, and can easily be differentiated from the local
"red spot" which occurs directly under the tip and is due to direct tissue injury.
E
The skin of the inner upper aspect of the forearm and the skin of the back was used
because it is known to be influenced relatively slightly by variations in blood flow and
vasomotor nerve impulses (5). It is desirable to use the skin of the back as well as that of
the forearm in patients with arteriosclerosis or other types of peripheral vascular disease.
(In normal persons, the threshold of flare on the back is slightly lower than on the forearm.)
The milliammeter readings refer only to the particular apparatus we used. They would be
applicable to another apparatus only if its electrical resistance or temperature of the ap-
plicator tip and its area of contact was the same. The approximate temperature of the tip of
the applicator when set at 850 ma. is shown in Figure 4. The temperature of the applicator
tip at various current intensities and under different uses is shown in Figure 2 A and B.
Apparatus No. II: The initial apparatus, though quite simple, did not permit a control of
the various physical factors involved in producing the flare. For example, we did not know
the temperature of the tip of the applicator before or after it made contact with the skin;
we could not maintain a constant temperature of the heater; we did not know if the rate and
amount of dissipation of heat might be more critical than the temperature at which flare
occurred. Though the initial apparatus was adequate to show a difference in the threshold of
flare between patients with and without cancer, it was inadequate for investigating the
underlying physiological mechanisms.
Two instruments, Model A and Model B, were then made by Dr. Victor Guillemin of the
Aeromedical and Physical Environment Laboratory of the University of Illinois. They were
essentially the same, except that one was operated with a dry cell battery and the other with
To
Fin. 1. Wiring diagram of Apparatus 1
* This apparatus was designed by Dr. Carl C. Pfeiffer, Department of Pharmacology,
University of Illinois, for the study of the effect of drugs on pain threshold.
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FIGs. 2a and b. Temperature of the applicator tip of Apparatus 1 at various current in-
tensities and under the conditions of different uses.
alternating current. The instruments were unique in that the applicator (Figure 3) to be
applied to the skin contained an electrical heater and thermometer. If the temperature of
the heater was maintained at a fixed level, the heat dissipation could be measured. If the
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FIG. 3. Photograph of skin applicator
TABLE 1
Summary of tests on skin flare thresholds with apparatus no. I
NO. OR CASRI
CONDITION NORMAL TEST LESS
THAN 550 ma.
NO. OR CASES
ABNORMAL TEST
555 ma. OR MORE
Cases in which the interpretation of the results is certain
1. Normal cases
2. Benign tumors
3. Non-tumor disease
Total
4. Proven malignant tumors
5. Superficial ca. of the skin
6. Secondary infection of n ca
Total
77
32
340
449
4
4
6
14
0
0
0
0
335
0
0
335
7. Hodgkins disease
8. Brain tumors
9. Diagnosis of a possible, but not proven malignancy
10. Diagnosis of a non-malignant disease
11. Cancer diagnosis
6
5
0
0
5
14
8
9
8
0
A. Total cases = 853.
B. Cases proven to have or not to have a malignancy, items 1, 2, 3, 4, 5 and 6 = 798.
C. Total proven cases of ca. or non-ca. = 788.
D. Omitting cases under 5 and 6 = 798.
E. Including cases of Hodgkins with 1, 2, 3, 4, 5, 6 = 818.
heat energy was fixed, the thermometer gave the temperature of the heater at any given
instant.
This apparatus has been described elsewhere (6) and will not be described here. The
results are the same regardless of the heater used, but the readings in milliamperes differ
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as these machines were handmade and no standardized equipment was used. This must be
borne in mind in reading the data in the tables.
OBSERVATIONS MADE WITh APPARATUS NO. 1
The flare threshold of 913 subjects was determined, the test being repeated
several times in most patients under approximately the same environmental
TABLE 2
Snmmary of the conditions in which the Skin Flare Threshold Test has been vsed, the initial
apparatns no. 1 being employed, showing the difference of reaction of malignant and non-
malignant disease
TIIEESHOLD OF
NON.MALICNANT CONDIIIONS NO. OF CASES FLARF.MfLLI-
MEAN
1. Normals
2. Benign tumors
3. Non-malignant disease
Total non-malignant
77
32
340
449
747
771
769
761
MALIGNANT CONDITIONS
4. Proven malignant diseases
5. Secondary infections of en
6. Superficial skin cancer
Total
7. llodgkins disease
8. Brain tumors
Total
Total malignant conditions
339
6
4
349
20
13
33
382
902
775
781
850
844
9. Positive test with diagnosis of possible but not proven
malignancy 9
10. Positive test some some non-malignant disease 8
11. Negative tests with a clinical diagnosis of cancer 5
Total 12
12. Patients with proven cancer but which are under active
treatment 60
Grand Total 913
conditions (Table 1). Among the 913 subjects, 449 were known with consider-
able certainty not to have malignant disease, and 349 were known to have a his-
tologically proven malignant tumor and were not under active x-ray or steroid
therapy at the time of testing. Twenty patients with the proven diagnosis of
Hodgkin's disease are considered separately. In 35 of the 913 patients (Table 2,
items 8, 9, 10, 11) there was a question whether the tumor was malignant or
whether the diagnosis of the non-malignant disease was correct. In the remain-
ing 60 patients some type of active therapy was in progress.
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It was observed that, if the threshold of flare was less than 850 ma. (the cur-
rent required in Apparatus No. 1 to bring the applicator to the threshold tem-
perature for flare), the patient very likely did not have a proven cancer. Using
TABLE 3
Showing types and numbers of patients with non-malignant disease who gave a threshold of
flare in the non-malignant range with apparatus no. 1
NUMBER AVERAGE
Peptic ulcers 35 668.5
Diabetes mellitus 21 782.1
Endocrine 24 730.2
Liver diseases 18 766.6
Lung diseases 18 765.6
Heart diseases 21 765.5
Kidney diseases 6 779.2
Gastrointestinal disturbances 13 765.4
Hernia 11 747.7
Hemorrhoids 6 783.3
Skin diseases 9 729.0
Neurology 16 767.1
Tuberculosis (active)* 13 765.3
Arthritis 14 773.2
Allergy 10 765.0
Post-operative 10 747.5
Pregnancy 10 752.5
Arteriosclerosis 13 796.1
Pernicious anemia 14 783.9
Secondary anemia 8 787.5
Obesity 5 780.0
Blood discrasia 5 765.0
Brain injuries 8 775.0
Paraplegia 6 758.0
Inflammatory conditions 7 785.7
Peripheral vascular 9 750.0
Boek's sarcoid 2 800.0
Paget's disease 1 775.0
Cachexia 1 750.0
ACTH (arthritis & L.E.) 5 735.0
Total 340
* Early cases.
this criterion, Table 2 was compiled to bring out this difference of reactivity
between malignant and non-malignant disease.
In Table 2 it will be noted that a threshold indicating the absence of a malig-
nancy was observed in 4 cases of superficial carcinoma of the skin and in 6 cases
of pyogenic infection of a carcinoma. The low flare threshold in the patients with
a brain tumor may have been due to the possibility that the brain tumors tend
to be pathologically benign. The low value in Hodgkin's disease may have been
THRESHOLD OF SKIN FLARE 473
TABLE 4
Showing types and location of the cancer according to the organ
NUMBER AVERAGE
Stomach 926.4
Lungs 37 892.5
General carcinomatosis 12 923.3
Lower gastrointestinal tract 47 907.9
Internal organs 21 900.0
Uterus 15 896.6
Mouth 36 893.0
Lymphosarcoma 15 878 3
Lympho-blastoma)
Leukemia 18 925.0
Skin 27 887.0
Thyroid 11 866.8
Esophagus 10 883.0
Larynx, pharynx 10 893.0
Neuro-reticule sa 6 896.0
Weing's sarcoma 2 900
Breast 21 902.3
Prostate 10 930
Others 2 925
Total 335
TABLE 5
Showing the type of patient which gave doubtful or erroneous results
NUMI3ER RANGE
A. Positives without proven malignancy
Patients without proven diagnosis
Arteriosclerosis
Pernicious anemia with icterus
Hypertension
Foreign body in brain
Brain hemorrhage
Tabes dorsalis
Obesity
9
2
1
1
1
1
1
1
850+
850-1000
1000
850
850
850
950
850
B. Negatives with apparent malignancy
Patients without proven diagnosis of ca 5
Cancer of the parotid gland* 1
Lymphosarcoma* 1
Cancer of the stomach, hermaphrodite* 1
Cancer of the nasopharynx* 1
750-825
725
825
800
750
* These are unequivocal errors and are shown in Table 6, Item 4.
due to the known fluctuation of disease activity. Further study would be re-
quired to answer the questions raised by these discrepancies.
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Table 3 shows the type of non-malignant diseases the "control patients"
bad, and Table 4 the location or type of malignancy which the "cancer patients"
had. Table 5 shows the type of patients in which the flare threshold failed to
indicate the absence or presence of a malignancy.
The results of the effect of treatment of the malignant disease on the flare
threshold is shown in Table 6. It is to be noted that the administration of steroid
hormones was quite consistently associated with a flare threshold characteristic
of a non-malignant condition.
TABLE 6
Effect of treatment on the Skin Ftare Test for n2atignant tninor disease nsing the initial
nppnratns (, 1)
TREATMENT
TORESISOLD MIT.LLSMPERE
NO. OF CASES
Avenge Range
22 775 650—850
7 798 700—875
25 828 750—1000
16 797 725—850
REMARKS
Ca. of breast receiving steroids
Ca. of prostate receiving steroids...
1 to 4 hours after x-ray treatment of
a cancer5
Surgically "cured" I to 5 years
1 patient gave
positive test
1 patient gave
positive test
1 not cured as per
flare test
Total
I\Iinus 10 patients included in
Table 2t
70
10
Corrected Total 60
* The x-ray treatment caused the test to be negative in 16 of the 25 patients. In some of
the 16 patients this was of the nature of an immediate effect and in others of an accumula-
tive effect indicating a destruction of the cancer.
t The 10 cases ore subtracted because they were tested before x-ray treatment was
started, and hence were included in the 339 cases in Table 2, Item 4.
The influence of age, sex, skin color, arteriosclerosis, hemoglobin concentration on
the flare threshold
It was thought that age might influence the results because of changes in the
blood vessels. In order to determine whether this supposition might be true the
resnlts on the non-cancer patients and cancer patients in Table 1 were dis-
tributed by decade. The results, shown in Table 7, indicate that age does not
significantly affect the distribution. However, age tends to increase the threshold.
The patients tested were taken as we saw them and avithout any attempt to have
the same number in each group.
The results in Table 8 sho\v clearly that sex has no marked effect on the skin
flare reaction.
In patients with advanced arteriosclerosis the reading is more difficult to make.
Therefore, more "false positives" occurred in patients with arteriosclerosis or
a
a
THRESHOLD OF SKIN FLARE 475
peripheral vascular disease than with any other disease (Tables 3 and 5). The
reading becomes less difficult after one has performed over 100 tests and be-
comes experienced in reading the preseace or absence of flare.
The reading was made with difficulty in Negroes because of the very dark
skin. Therefore, we did not include many Negroes in this series of cases.
TABLE 7
Showing that the skin flare in cancer and non-cancer patients is not infloenced by age to a
significant extent
DECADE NO. OF PATIENTS MEAN THRESHOLD NO.02 PATIENTS DEAN THRESHOLD
0-9 1 650 0
10—19 21 713 0
20—29 72 743 19 887
30—39 76 756 40 881
40—49 81 773 58 885
50—59 82 776 92 918
60—69 70 781 124 924
70—79 37 788 68 922
80—89 14 782 26 934
TABLE 8
The effect of sex on the skin flare reaction in patients with and without cancer
MALES FEMALES
TOTAL NO. ____________________ ____________________
No. Threshold No. Threshold
Normals 77 52 749 25 743
Benign tumors 32 29 770 3 775
Non-malignant disease 340 253 771 87 768
Total 449 334 759 115 762
Cancer 335 214 923 121 897
Hodgkin's diseasa 20 18 850 2 825
Brain tumors 13 13 844
Sacondary infection of cancer 6 6 775
Skin cancer 4 3 775 1 825
Total 378 254
827 588
902
822
124
239
889
821Grand total
Hemoglobin concentration of the blood did not render the reading difficult
or inaccurate until the concentration was quite low, 3.5 grams per 100 cc. of
blood or less.
OBSERVATIONS MADE WITH APPARATUS NO. 2
The Apparatus No. 2 is calibrated so that 0.01 ma. is equivalent to 0.2° C.
On the Use of Appratus No. : There are several methods by which the appa-
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ratus No. 2 might be used. (I) The temperature of the applicator tip might be
fixed in air, and the tip then applied to the skin and its temperature maintained
regardless of the energy required to hold the applicator at a fixed temperature
when in contact with the skin, or regardless of the rate of dissipation of heat
chiefly by the skin temperature and blood flow. (II) The energy input might be
fixed and maintained after applying the applicator to the skin without regard
to the temperature of the tip. (III) The temperature of the applicator after
applying it to the skin might be raised to a desirable level within a certain
period of time at which level it is maintained. Since so little is known regarding
the several factors that may be concerned in producing a flare with heat and
their relative importance, all three possible methods had to be tried, and the
best one selected on the basis of actual experimental results.
Method I. (a) The temperature of the applicator-tip is prepared at room temperature
(ordinary room temperature in winter and summer is adequate, vide infra) during a period
of 30 seconds by adjusting the heater current (meter C) until the desired temperature is
obtained, which in Figure 2 was 44.5°C. (h) The applicator tip is then applied to the skin of
the inner, upper aspect of the forearm for one minute during which time the temperature of
the tip is maintained. Then, the tip is removed from contact with the skin. (c) If no flare
or one measuring less than 15 mm. in its maximum diameter is obtained after waiting for
1 to 3 minutes, the procedure under "a" and "b" is repeated after increasing the heater
current (meter C) so that the temperature of the tip is increased 0.4°C. or 0.02 ma. (meter B)
at each subsequent trial, until no flare is observed. The first reading where flare (measuring
at least 15 mm. in diameter) occurs is taken as the threshold.
Method II. (a) The applicator tip without preheoting is applied to the skin and the heater
current (meter C) is immediately set at 24 ma. This amount of current was selected because
it heats the applicator tip while on the skin so that the temperature of the tip toward the
end of the one minute period of application ranges between 43.4° and 49.4°F. (Figure 4,
III) according to the individual subject. (h) After one minute the applicator tip is removed
from contact with the skin. (c) If no flare is observed after waiting for 2 or 3 minutes, the
heater current is increased at each subsequent trial by 1 ma. on the heater dial, or meter C.
(d) If a flare is obtained and if its maximum diameter is more than 14 ma., the heater current
is decreased at each subsequent trial by 1 ma, until the threshold is ascertained.
Method III. The applicator tip without preheating is applied to the skin and the heater
current (meter C) is regulated so that after 15 seconds the temperature meter, or meter B,
shows a reading of 0.52 ma., which is equivalent to a temperature of 45.8°C. (b) The tem-
perature is then kept at this level for one minute, and then the applicator tip is removed
from contact with the skin. (c) If no flare is observed after waiting for 2 or 3 minutes, the
heater current (meter C) is increased so that the reading of the temperature meter (meter B)
is increased 0.02 ma., or 0.4°C. at each subsequent trial until a flare of threshold size is ob-
tained (15 mm.). (d) If a flare is obtained and if its diameter is more than 14 mm., the
heater current is decreased so that the reading of the temperature meter is decreased 0.02
ma., or 0.4°C. at each subsequent trial until no flare of a threshold size (15 mm. or more) is
obtained.
RESULTS OBTAINED FROM THE COMPARISON OF THE THRRE METHODS
The results are summarized in Table 9. The data show that Method III is
superior to the other methods. The accuracy of Method III approaches the ac-
curacy of the initial method and apparatus.
Reference to Figure 4 shows how the method with Apparatus No. 1 and the
three methods with the new Apparatus No. 2 vary as regards the mean tem
perature applied to the skin through the applicator tip and the energy input.
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TABLE 9
CANCERS
Right Wrong
CONTROLS TOTAL
Right Wrong Cases Errors
ERRORS
1st method 82 10 89 16 171 26 15.2
2nd method 51 7 58 6 109 13 11.9
3rd method 160 2 87 4 247 6 2.4
Total 293 19 234 26 527 45 8.5
FIG. 4. Schematic comparison of the heat and energy factors of the different methods of
application. In all figures the dotted lines represent energy and the solid lines heat.
No. I shows the old method. The temperature varies biphasically during the minute of
application and the energy input is constant.
No. II shows the method I of application with the new apparatus. The temperature re-
mains constant during the minute of application and the energy input is variable.
No. III. In method II of the new apparatus the temperature varies monophasically dur-
ing the minute of application and the energy input is constant.
No. IV. In method III there is a 15 second preheating period on the skin. After that dur-
ing the minute of actual stimulation the temperature remains constant and the energy varies
monophasically over a comparatively small range.
A study of the diagrams in Figure 4 and the data in Table 2 and Table 9 in
relation to the predictive value of the initial method and the three new methods
Comparison of the S different methods of flare prodvetion with model B of apparatns no. 2
I
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suggests that a relatively low mean temperature of around 44.0° C., applied for a
minute, is critical in differentiating the flare threshold of patients with and
without malignant neoplastic disease. The following procedure was followed
when using Apparatus No. 2 for obtaining the data summarized under the
"3rd method" in Table 9 and in making the observations in the remainder of
this report.
SPECIFIC LI5T OF INSTRUCTION5 FOR THE FLARE TE5T
1. Turn on main switch M and adjnst meter A with Knob 1 and 2 to 40 ma. This balances
the instrument and should be checked occasionally between measurements.
2. Turn off switch M.
3. Place heating element on skin, holding it so that the pressure is purely that of its own
weight.
4. Turn on main switch M and with the help of Knob 3 and 4 increase the energy input
such that after 15 seconds meter B is on 0.52 ma. (45.8°C).
5. By control of energy with Knob 3 and 4 this level of 0.52 on meter B is maintained for
one minute.
6. Turn off main switch M.
7. Read and measure with skin flare.
8. If no flare is present, repeat steps 3 to 7, while increasing the heat on meter B by steps
of 0.02 ma., until a definite flare is observed.
If there is a definite flare repeat steps 3 to 7, while decreasing the heat on meter B in
steps of 0.02 ma., until a threshold is established. (A flare with a maximum diameter of 15
mm. or definitely larger than the "red spot" under the applicator is required.)
THE VARIATION IN THE THRESHOLD OF FLARE IN TIlE SAME SUBJECT
Patients with and without malignant disease were systematically studied with
Apparatus No. 2A.
The results in Table 10 show that no significant variation was found during
the day. For example the patient with cellulitis did not show a flare reaction
with 0.50 ma. hut did with 0.52 ma. at 8:00, 12:00, 4:00 and 8:00 o'clock.
The results in Table 11 show that the patient with cellulitis showed no flare
reaction with 0.50 ma. on any one of 10 consecutive days, but did show a flare
reaction at 0.52 ma. on each of 10 consecutive days.
THE EFFECT OF THE EXTERNAL ENVIRONMENTAL TEMPERATURE ON
THE THRESHOLD OF THE FLARE REACTION
Our observations on the 913 subjects reported ill Table 2 did not indicate
that the variations in environmental temperature which occur at ordinary room
temperature had any significant effect on the threshold of the flare reaction.
Nevertheless, it was decided to collect some systematic data on the subject.
Accordingly, eight normal subjects were selected and the threshold of their
flare reaction was determined by method III, along with the energy input, with
a controlled room temperature of 70° F., 33° F., and 108° F.
The results are shown in Table 12. It will be noted that the threshold of flare
as regards temperature was not influenced by environmental temperature. How-
ever, the amount of energy required to maintain the temperature of the appli-
cator tip varied directly with the environmental temperature.
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This would indicate, as is true of arteriosclerosis, that the rate of blood flow
through the skin or the temperature of the skin are not important factors in
determining the threshold of flare with this method.
TAI3LE 10
Variation of the threshold of flare and pain during one day apparatns model 2-A
NO. DIAGNOSIS SEX AGE THRESHOLD OF FLARE IN ma. 1/100 ma. THRESHOLD OF FASNIN ma. SN 1/100 ma.
1 Cellulitis M 37 50: 52: 54: 66, 73, 62, 61
0 1,2,3,4* 1,2,3,4*
2 Infected burn of face M 34 46: 48: 50: 50, 59, 56, 61
3 1,2,3,4 1,2,3,4,
3 Frostbite amputation M 44 46: 48: 50: 71, 75, 71, 66
ofbothfeet 0 1,2,3,4 1,2,3,4
4 Cancer of the esopha- M 50 54: 56: 52: 54, 53, 53, 46
gus 0 0 1,2,3,4
5 Stasislegulcer M 59 48: 50: 52: 65,61,65,58
2,3,4 1,2,3,4 1,2,3,4
6 Rheumatic heart dis- F 54 48: 50: 52: 56, 50, 60, 56
ease. Congenital 0 2, 3, 4 1, 2, 3, 4
failure
7 Rheumatic heart dis- F 26 46: 48: 50: 47, 49, 58, 54
ease. Decompensa- 0 1, 2, 3, 4 1, 2, 3, 4
lion
8 Recent C.V.A. Paral- F 79 52: 54: 56: 57, 64, 59, 56
ysis left sidet 0 0 1, 2, 3, 4
9 O.R.D. Decompensa- F 66 48: 50: 52: 70, 65, 66, 70
tion coronary oc- 0 2 1, 2, 3, 4
clusion
* The numbers give the time of the day, when a positive reaction was obtained; 1 =
8:00 am, 2 = 12:00 noon, 3 = 4:00 pm, 4 = 8:00 pm.
* Taken at 8:00 am, 12:00 noon, 4:00 pm, and 8:00 pm, respectively.
t This patient is now being checked for possible malignancy.
It was observed in a few tests that immersion of the arm immediately before
the test for 5 minutes in either warm water (43° C.) or cold water (14° C.)
raised the threshold.
THE EFFECT OF CERTAIN DRUGS ON THE THRESHOLD OF FLARE REACTION
From the viewpoint of the mechanism of the flare reaction, it was considered
important to study the effect of certain drugs. Such empirical knowledge per se
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TABLE 11
Variation of the threshold of flare and pain during 10 consecutive days (model A)
NO. DIAGNOSIS SEX AGE THRESHOLD OF FLARE THRESHOLD OF PAININ ma. IN 1/100 ma. in ma. IN 1/100 ma.
1
2
3
4
5
6
7
8
9
Cellulitis
Infected burn of face
Frostbite amputation of both feet
Cancer of the esophagus
Stasis leg ulcer
Rheumatic heart disease. Congenital failure
Rheumatic heart disease. Decompensation
Recent C.V.A. Paralysis left side*
O.H .D. Decompensation. Coronary occlu-
sion
M
M
M
M
M
F
F
F
F
37
34
44
50
59
54
29
79
66
50: 52: 54:0, 10 10
46: 48: 50:0 3 10
46: 48: 50:0 9 10
54: 56: 58:
0 6 10
48: 50: 52:0 7 10
48: 50: 52:
0 6 10
46: 48: 50:0 8 10
52: 54: 56:0 2 10
48: 50: 52:0 5 10
Mean 66
s.e. 1.63
Mean 55
Mean 65
s.e. 1.93
Mean 57
s.e. 2.74
Mean 59
s.c. 2.03
Mean 57
se. 1.42
Mean 49
s.e. 1.29
Mean 61
s.e. 2.31
Mean 64
s.c. 2.11
The figure gives the number of positive reactions at the indicated level.
* This patient is being checked for possible malignancy.
TABLE 12
Showing that the external environmental temperature of the patient has no effect on the flare
threshold as regards the temperature of the applicator tip but does have an effect on the
quantity of energy input
TEMPERATURE NO. OF SUBJECTS INSTRUMENT
FLARE ENERGY INPUT
Mean Range Mean Range
ma. ma. ma. ma.
70° F. 8 New 0.53 0.50—58 24 18—32
Room temp. Model B S. e.* 0.01 S. e. 1.82
33° F. 8 New 0.53 0.50—.58 34 26—44
Cold room Model B S. e.° 0.013 S. e. 2.84
108° F. 8 New 0.53 0.50—58 17 13—20
Hot room Model B S. e.* 0.01 5. e. 1.61
* S. e., standard error.
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is also important from the viewpoint of the interpretation of the test, since
patients may receive drugs for therapeutic purposes, especially morphine for
pain.
After determining the threshold of flare the subject was injected with a thera-
peutic or diagnostic dose of histamine, pyribenzamine, adrenalin, or morphine.
The results (Table 13) show that histamine (0.01 mg. per kg.) and adrenalin
(0.25 cc. of 1:1,000 solution) did not change the threshold of skin flare, but had
a marked influence on the energy required to obtain and maintain the threshold
TABLE 13
Showing the Effect of Systemic Injection of Certain Drugs on the Flare Reaction
(8 normal subjects, New Model A)
ENERGY IN MA
THRESHOLD OF
SKIN FLARE (MA)
Mean Se.
SIZE OF FLARE (MM)
Mean Se.
Control
Histamine, (0.01 mg/kg)
Adrenalin, (0.25 cc
1:1,000)
Morphine, (10 mg)
0.26
0.26
0.26
0.30
16.5
19.2
16.2
21.5
0.3
0.4
0.3
0.5
19.1
21.6
19.6
22.1
1.9
2.1
1.7
2.4
TABLE 14
Showing the effect of an intradermal injection of certain drugs on the flare reaction at the site
of injection
SIZE OF FLARE IN
DIAMETER IN mm. ENERGY IN ma.
SUBSTANCE NO. OF SUBJECTS INSTRUMENT
Mean Range Mean Range
Saline 0.1 cc. 8 New
Model A
32
S.c. 0.58
23—29 29
S.e. 1.80
27—31
Adrenaline 8 New 36 32—41 27 25—30
0.1 cc. 1:4000 Model A S.c. 1.43 S.c. 1.43
Histamine 8 New 46 39—58 31 29—32
0.1 cc. 1:4000 Model A S.c. 1.7 S.c. 1.91
temperature. The effect of adrenalin is not statistically significant. But the trend
is clear, and a larger dose or a greater number of tests might decrease the energy
unequivocally.
Pyribenzamine (100 mg. by mouth) did not influence the threshold in 8 sub-
jects; a larger dose may do so.
Morphine sulphate (10 mg.) unequivocally raised the threshold. This effect of
morphine was found only in this series and may influence some of the early re-
sults. Later on patients under morphine were excluded.
Table 14 shows that the intradermal injection of vaso-active drugs produces
results comparable to those of their systemic effect.
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Of the drugs tested in this series only morphine changed the threshold and
could produce a quasi-malignant response.
OTHER OBSERVATIONS
A number of patients were studied for a prolonged period to determine the
effect of various other factors. The results will be briefly summarized.
Surgery. An operation on a non-malignant condition had no effect on the
threshold in 12 patients. In 14 patients on whom surgery was performed with-
out removal of the tumor, the flare threshold was not significantly changed. In
five patients it was found that general anesthesia raised the flare threshold. In
11 cancer patients in whom the surgical operation relieved pain due to pressure
or obstruction the flare threshold was not affected. In 3 of 5 patients in whom
orchiectomy for carcinoma of the prostate was performed and in whom pain
was relieved and the clinical picture was otherwise improved, the flare threshold
was decreased. In the remaining 2 the clinical condition was not benefited and
the flare threshold was unchanged.
Fever had no significant effect on the flare threshold in 9 patients tested.
A blood transfusion temporarily lowered the threshold in 7 out of 8 patients
with a carcinoma. Oxygen inhalation may also lower the flare threshold.
Steroid Therapy. In 11 patients with carcinoma of the prostate, steroid ther-
apy improved the clinical condition and decreased the flare threshold in 6. In
5 patients who had carcinoma of the breast and had received steroid therapy
the flare threshold was decreased in all and definite clinical improvement oc-
curred in five.
X-ray Therapy. A single x-ray treatment was followed by n decrease in the
flare threshold in 3 out of 34 eases, and a complete series of treatment in 5 out
of 14 cases.
ON THE MECHANISM OF THE ELEVATED THRE5HOLD OF FLARE IN
PATIENTS WITH MALIGNANT Df5EASE
Lewis (1) has extensively studied the mechanism of cutaneous flare in re-
sponse to various types of noxious excitants. His observations indicate that the
red reaction or "red spot," which occurs directly under the site of application
of the noxious excitant, is due to a dilation of the minute vessels of the skin
and does not involve any significant change in blood flow The surrounding
flare reaction, on the contrary, is due to a dilation of arterioles which results in
a forward movement of blood. The dilation of the arterioles is due to an axon
reflex because a flare reaction occurs for several days after the nerve supply to
an area of the skin has been cut but not after the nerve has degenerated. Lewis
has also presented strongly presumptive evidence showing that the axon reflex,
which causes flare, is excited by the release of histamine or an H-substance. It
is quite certain that histamine or a histamine-like substance is released when the
skin is irritated to produce an extensive flare because gastric secretion is stimu-
lated (7, 8).
It should be pointed out that Lewis (1) has reported that in urtiearia the skin
is more susceptible to mechanical injury, as regards the production of flare and
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a wheal, than to thermal, chemical, or electrical injury. If this is true, then the
elevated heat flare threshold in cancer is not analogous to a condition opposite
to that of urticaria, i.e. a condition in which the skin is less susceptible to injury.
Nevertheless, it is possible that the incidence of urticaria and allergic states
may be lower in the cancer than in the noncancer patient.
On the basis of what is known regarding the mechanism of the flare reaction,
the threshold of the reaction could be elevated in the following ways:
I. A relative inadequacy of H-substance, due to:
A. Decrease in production caused by a deficiency of the cellular enzymes
which releases histamine.
B. Increase in rate of destruction of the released histamine by his-
taminase.
II. An increase in the threshold of stimulation of the sensory nerve ending
or of the axon reflex.
III. Arteriolar Hypertonus, due to:
A. Increased vasoconstrictor nervous tone.
B. Vasoconstrictor substance in the circulation released by cancer cells
or by effect of cancer cells on adjacent or distant body cells.
C. Abnormality of acetylcholine-cholinesterase system in the arteriole
(Dale), or some abnormality of the motor-effector limb of the axon
reflex.
(I) A decrease in production of H-substance could result from a deficiency
of the proteolytic enzyme which releases histamine on the application of a pain
stimulus or on tissue injury (7, 8, 9). If the histaminase content of the skin were
increased, the histamine or H-substance released would probably be destroyed
more rapidly. In either case, a more intense noxious stimulus would be required
to cause a flare reaction. (II) The only evidence in support of an increase of
threshold of the nervous excitation or transmission is that morphine which, as
is well known, has some peripheral action on blood vessels increases the threshold
of flare. Also with advancing age there is an increase in threshold of both cu-
taneous pain and flare, as shown above. (III) If there is an increase in arteriolar
tone, a more intense stimulus would be required because more H-substance
would have to be released to stimulate more intensely the sensory endings of
the axon reflex to produce the greater than normal amount of acetylcholine
which would be required to cause arteriolar dilation.
The foregoing presentation is only a partial analysis of the problem, but it is
probably adequate for the interpretation of the results to follow.
The Threshold of the Histamine Flare in Subjects With and Without Cancer.
It was thought that the determination of the threshold of the histamine flare
in subjects with and without cancer would throw some light on the foregoing
analysis, of the mechanism of the elevated flare threshold in subjects with
cancer.
Accordingly, 20 subjects with and without cancer were injected intradermally
with 0.1 cc. of a normal saline solution containing a concentration of histamine
phosphate varying from 1:100,000 to 1:1 million.
The results are shown in Table 15. A Chi square analysis of the data show
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that the differences are statistically significant; so, we may be reasonably certain
that the histamine flare threshold is higher in a group of subjects with cancer
than without cancer. However, a clear cut line of demarcation between the
threshold of the subject with and without cancer was not found. Apparently the
heat threshold of flare is either more critical or more sensitive due to ease of
control than the intradermal histamine flare.
Our interpretation of these observations is as follows: (IA) Since a known con-
centration of histamine was injected, the factor of a deficiency of production
was controlled in the foregoing experiment. However, it is reported that the
anti-proteolytic (antichymotryptic) activity of the serum is elevated in the
TABLE 15
Flare reaction to histamine phosphate in normal saline solution when 0.1 cc. was injected
intradermalty into 20 subjects with and 20 without cancer
SUBJECTS OIVIMO A POSITIVE
StARE RESPONSE
BISTAMINE CONCENTEATION USED 20 subjects 20 subjects
without cancer with cancer
No. % No. %
1:100,000 20 100 16 80
1:200,000 19 95 15 75
1:300,000 19 95 12 60
1:400,000 19 95 8 40
1:500,000 17 85 6 30
1:600,000 13 65 4 20
1:700,000 11 55 3 15
1:800,000 8 40 1 5
1:900,000 7 35 1 5
1:1 million5 7 35 0 0
Mann threshold concentration 1:700,000 1:345,000
20
20
35
55
55
45
40
35
30
35
* Control tests on 10 persons using normal saline solution did not cause a flare reaction.
Chi square analysis of the two groups yielded a probability of less than 0.01.
cancer patient. Unfortunately, this is not specific for the cancer patient (10, 11),
and hence cannot be correlated with the apparently high degree of specificity of
the heat flare reaction we have observed. (TB) If there were an increase in the
histaminase in the skin of the cancer patient, then, even though a known con-
centration of histamine was injected, it could be destroyed faster, and hence a
higher concentration would be required. This possibility is unlikely because in
human pregnancy the serum histamine is increased 1,000 times, but we found
the heat flare threshold to be normal (Table 3) and Wicksell (12) found the
histamine flare to be normal in uncomplicated pregnancy. (III) Since we can
find no significant evidence to support the possibility that there is an inade-
quacy of H-substance produced by the skin of the cancer patient, we are in-
clined to believe that an arteriolar hypertonus exists in the skin of the cancer
D5PPEEENCE
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patient. (lilA) There is no evidence supporting increased vasoconstrictor-
nerve tone in the cancer patient. (IIIC) Arteriolar hypertonus in cancer vould
appear not to be due to a disturbance of the acetyicholine-cholinesterase mech-
anism because the flare test is normal in complicated pregnancy, and estrogens
which are present in large quantities in uncomplicated pregnancy stimulate the
production of cholinesterase (13, 14). (II) Although our evidence on the effect
of morphine and ageing on the threshold of flare and pain indicate that the
theshold of the sensory limb of the axon reflex may be raised in the cancer pa-
tient, we are at present inclined to interpret our evidence and that obtainable
in the literature as indicating that the high threshold of flare in the skin of the
cancer patient is due to a circulating vasoconstrictor substance, such as
"pitressin for a lack of a better analogy (15). The presence of a normal flare
threshold in the cancer patient, alter sex hormones are given, or when sub-
stances are absorbed from a suppurating cancer, both of which are vasodilating
(1 6a), support the presence of an arteriolar hypertonus. Table 16 shows the re-
TABLE 16
ihe figures in the table give the number of subjects with a positive response (10 cancer patients,
10 controls)
CoNCENTRATION OF AcETYLCH0UNE* WITHOUT CANCER WITH CANCER
1:100 10 9
1:1,000 8 6
1:10,000 5 3
1:100,000 3 2
The differenca betwean tha two groups is not statistically significant.
* Acetyicholine chloride (Merck) given intradermally. Only a fresh solution was used
and it was used within two hours after it was made.
sults of intradermal injections of Acethylcholine Chloride (Merck). As the vaso-
dilation caused by this substance is due to a direct effect on the blood vessels,
this could be a test for the presence of a vasoconstrictor substance in the blood
of the cancer patient. Though the difference observed between the two groups
(Table 16) is not statistically significant the trend suggests that a significant
difference might be obtained by the use of a more refined technique.
Source and Nature of the Vasoconstrictor Substance. If a vasoconstrictor sub-
stance is produced in the presence of cancer, two questions arise: (A) What is the
course of the substance? and, (B) Why does uot a rise in blood pressure occur
in the cancer patient?
The source might be from the cancer cell, or from the aseptic necrosis of
normal body cells due to the invasion of the cancer cell, or to the effect of the
cancer on some organ such as the posterior lobe of the pituitary gland or adre-
nal. The only instance where it is known that a vasoconstrictor substance is
released as the result of asceptic necrosis, and frequently without a rise in blood
pressure, is the early pre-eclamptic state. It is unknown whether the constrictor
substance comes from the dying or dead trophoblast or from the effect of the
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entrance of large amounts of thrombokinase which enters the blood (16b) and
on reacting with the blood platelets releases a vasoconstrictor substance (17).
According to this supposition the skin flare should be elevated in eclampsia
and we have found it to be elevated in 5 of 7 patients examined to date by us.
An increase of pituitrin in the circulation should also increase the threshold of
flare according to the observations of Krogh (15) and of Lewis (1). However,
no tendency toward the production of concentrated urine by the cancer pa-
tients has been observed.
Like all effects of phenomena when first observed, the cause or causes of the
elevated threshold of flare in the cancer patient is conjectural and the possi-
bilities numerous.
GENERAL DI5CUSSION
It is remarkable that a vasomotor skin reflex should be modified similarly
and to some extent quantitatively by various types of malignant aeoplastic dis-
ease. Moreover, it appears that if the cancerous growth is temporarily inhibited
or removed the effect disappears. Yet, all of those optimistic persons, who are
working to find a non-morphological general diagnostic test for cancer, base
their hope on the belief that there is something physiologically unique and
characteristic about cancer or its effect on the host.
Is this effect of malignant growth due to the production by the cancer cell of
a substance which affects the vascular reflex? Or, is it due to an indirect effect
induced by the cancerous growth? In answer to the first question, we know that
the ovarian granulosa cell tumor of the mouse exerts an effect on the capillary
vessels of the liver and some other organs (18). In this case the possible presence
of the hormone was easily recognized; could not have been missed, and was
easily identified. May not cancer cells give off an arteriolar constrictor substance
which would function to divert blood away from normal tissue to itself to insure
its own growth. In answer to the second question, it is known that the adrenal
gland is secondarily affected in tumor bearing animals and that cancer has
other effects on the host (19).
The majority of the patients who had a proven cancer and \vere tested by us
had a cancer that was well advanced but few were in the terminal stage of the
disease. It remains to be determined how far advanced the cancer must be be-
fore it causes a specific elevation in the threshold of skin flare. We only can say
that in the skin cancers we have seen, the flare threshold was not abnormally
elevated until the cancer had metastasized. But, whenever a physiological differ-
ence between a cancer and non-cancer host is observed, another opportunity
for an attack on cancer is provided.
SUMMARY
When an adequate degree of heat is applied to a small area of skin (forearm
or back) a reddening or a flare occurs about the site of contact. An apparatus
and method for its use is presented which allows the determination of the tem-
perature and energy input required to produce a flare reaction. In normal sub-
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jects and in patients without cancer the temperature required to produce a
flare reaction when the heat was applied to an area 3 mm. square ranged from
44° to 45.4° C.
The threshold of skin flare, when heat is the noxious excitant, did not vary
significantly in the same person under standard resting conditions during the
day and over a period of 10 days. Sex and room temperature do not affect the
threshold of flare. Age significantly increases the threshold of cutaneous flare
and pain up to the age of 60 after which a plateau occurs.
In 77 normal persons, 32 patients with proven benign tumors, and 340 patients
with various non-neoplastic diseases, the flare reaction was obtained within the
normal temperature range of from 44 to 45.4°. In 349 patients with proven
malignant neoplastic disease the temperature required to produce flare was
45.8° C. or higher in all but 14, including 4 patients with superficial cancer of
the skin and 6 with pyogenic infection of the cancer. The effect of age on the
flare reaction is not as great as that of cancer. Severe arteriosclerosis and marked
anemia render the reading of flare difficult and may yield a value within the
cancer range.
Steroid therapy is followed by a flare reaction within the temperature range
indicating the absence of malignant neoplastic disease. Most patients who are
clinically improved, and 15 of 16 patients who were "1 to 5 year surgical cures"
showed a lower flare response. X-ray therapy in some patients caused the flare
reaction to fall to the range indicating the absence of malignant neoplastic
disease.
The presence of malignant neoplastic disease increases significantly the thresh-
old of histamine flare. A concentration of histamine which uniformly differen-
tiates between persons with and without cancer was not found.
The mechanism concerned in the elevation of threshold of cutaneous flare in
the presence of cancer is discussed.
Much more study will be required to determine the possible value of "the
effect" we have discovered for the diagnosis and therapeutic prognosis of malig-
nant neoplastic disease.
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